The market for biotherapeutics is continually expanding as the pipeline for small molecules dries up. Early stage identification and characterization of those clones producing high levels of the therapeutic protein of interest is mandatory from a productivity standpoint. Despite the technical limitations of traditional ELISA —such as low throughput and limited reproducibility—many labs still rely on this approach to carry out assays on recombinant proteins, such as IgG clonal selection and characterization, which can hamper the identification of the best candidate drugs. In this webinar, our expert panel will review how new technologies can be used to analyze recombinant protein expression, maturation, and secretion.
During the webinar, you will:
- Hear about how the latest technologies are being applied to identify the optimal expression clones
- See recent data presented by our experts on their current projects
- Have your questions answered live during the webinar!
W. Clay Brown, Ph.D.
University of Michigan
Ann Arbor, MI
Dr. Brown began his career at Amgen in the Bacterial Expression group, which was formed to pursue development of the proprietary systems that were the basis of Amgen's production process for biotherapeutics. He then helped to establish the Mammalian and Insect Cell Expression group at Amgen, which later became part of the Protein Sciences department in Process Development. When he moved to Pfizer as the head of Expression Technologies, Dr. Brown was responsible for all in-house protein and cellular reagent provision at the Ann Arbor research site. He directed three separate groups, which produced reagents in bacterial, insect, and mammalian systems, as well as developing formats suitable for automation, and identifying and implementing technology for optimizing bioprocessing. Now at the University of Michigan, Dr. Brown is scientific director of the High-Throughput Protein laboratory in the Center for Structural Biology. The mission of his group is to provide support to life sciences researchers across the campus to identify constructs and conditions that lead to high yields of soluble protein expression in E. coli. He also concurrently pursues basic research into developing molecular biology tools such as alternative promoters, solubilizing fusion partners, and chemical lysis strategies.
Tim Beaumont, Ph.D.
Amsterdam, The Netherlands
Dr. Beaumont earned his Ph.D. at the University of Amsterdam in the Netherlands before his postdoc at the Gladstone Institute of Virology and Immunology in San Francisco, California. He joined the startup company AIMM Therapeutics, based in Amsterdam, the Netherlands, in 2004 where he developed a human B cell culture system that could be used for functional screenings against infectious disease targets. Dr. Beaumont and his group currently focus on the interactions of the immune system with pathogens, and their applications towards developing antibodies that can intervene in human diseases. Dr. Beaumont has been widely published and is the lead author on four patents.
Roger Bossé, Ph.D.
Dr. Bossé holds a Ph.D. in Pharmacology from the University of Sherbrooke in Quebec, Canada. He completed his postdoctoral training in Neuroendocrinology in Marc Caron’s laboratory at Duke University in North Carolina in the United States. Dr. Bossé joined BioSignal in 1996 as the R&D group leader responsible for the development of the G protein-coupled receptor pipeline. Following the acquisition of BioSignal by Packard in 1998, he was promoted to associate director of R&D and his team developed the AlphaScreen product line. After the merger between PerkinElmer and Packard BioSciences in 2001, Dr. Bossé and his team initiated the development of the AlphaLISA platform. In 2006, he transitioned to new functions in Business and Sales development. Dr. Bossé was elected on the Society for Biomolecular Sciences (SBS) board of directors in 2008 and also created a new Special Interest Group on drug repositioning within SBS.
Moderator: Tianna Hicklin, Ph.D.
Dr. Hicklin studied biology at Colorado State University for her undergraduate education before earning a Ph.D. in neuroscience from the University of Colorado Anschutz Medical Campus. Prior to joining Science/AAAS, she worked as a science writer intern for the University of Colorado’s Office of Media and Public Relations in Denver, Colorado and for Brookhaven National Laboratory’s Media and Communications Office in Upton, New York. Dr. Hicklin is currently the assistant editor for the Science/AAAS Custom Publishing Office.
For related products/technologies, go to: www.perkinelmer.com/biotherapeutics